Ad.IL-12 was administered in doses ranging from 2.5 × 10 10 to 3 × 10 12 viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients ...
Angiogenesis Inhibitor IM862 Is Ineffective Against AIDS-Kaposi's Sarcoma in a Phase III Trial, but Demonstrates Sustained, Potent Effect of Highly Active Antiretroviral Therapy: From the AIDS ...
ST. LOUIS--(BUSINESS WIRE)--Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results ...
Reprogramming the tumor microenvironment to increase immune-mediated responses is currently of intense interest. Patients with immune-infiltrated “hot” tumors demonstrate higher treatment response ...
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in ...
LOS ANGELES – Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute are working to develop a non-surgical approach to brain cancer that uses radiation and the injection of specially ...
BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback